Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
November 28, 2016 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of...
Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
November 09, 2016 16:30 ET
|
Esperion Therapeutics, Inc.
Presentation and Webcast on Wednesday, November 16, 2016 at 3:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical...
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
November 03, 2016 16:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...
Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
November 01, 2016 16:30 ET
|
Esperion Therapeutics, Inc.
Presentation and Webcast on Tuesday, November 8, 2016 at 3:00 p.m. Pacific Time/6:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....
Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
October 13, 2016 07:30 ET
|
Esperion Therapeutics, Inc.
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mgBempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and...
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...
Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
June 28, 2016 16:05 ET
|
Esperion Therapeutics, Inc.
On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter Aligned with global regulatory authorities on a consistent definition of statin intolerance Conference...
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
May 04, 2016 08:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
March 08, 2016 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 08, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 16:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...